for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avenue Therapeutics Inc

ATXI.O

Latest Trade

10.92USD

Change

0.01(+0.09%)

Volume

37,691

Today's Range

10.80

 - 

11.16

52 Week Range

4.96

 - 

12.34

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.91
Open
10.80
Volume
37,691
3M AVG Volume
1.07
Today's High
11.16
Today's Low
10.80
52 Week High
12.34
52 Week Low
4.96
Shares Out (MIL)
16.70
Market Cap (MIL)
182.23
Forward P/E
-17.74
Dividend (Yield %)
--

Latest Developments

More

Avenue Therapeutics Reports Q2 Loss Per Share $0.11

Avenue Therapeutics Reports Q1 Loss Per Share Of $0.08

Avenue Therapeutics Announces New Drug Application For IV Tramadol Accepted For Review By FDA

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Avenue Therapeutics Inc

Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing its product principally for use in the acute/intensive care hospital setting. The Company’s product candidate is intravenous (IV) Tramadol, for the treatment of moderate to moderately severe post-operative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Its Oral tramadol is marketed in the United States for moderate to moderately severe pain in adults. Its Parenteral tramadol formulations include IV, intramuscular (IM), and subcutaneous (SC) formulations. Tramadol is marketed in the United States under the trade name Ultram immediate release tablet. Ultracet is a combination product containing tramadol and acetaminophen, is also marketed in the United States.

Industry

Biotechnology & Drugs

Contact Info

2 Gansevoort St Fl 9

NEW YORK, NY

10014-1667

United States

+1.781.6524500

http://www.avenuetx.com/

Executive Leadership

Lindsay A. Rosenwald

Executive Chairman of the Board

Lucy Lu

President, Chief Executive Officer, Director

Joseph Vazzano

Chief Financial Officer, Principal Financial Officer and Corporate Secretary

Jaideep Gogtay

Director

Garrett Ingram

Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-2.100

2019

-1.650

2020(E)

-0.630
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
44.43
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-119.82
Return on Equity (TTM)
-102.69

Latest News

Latest News

BRIEF-Avenue Therapeutics Reports Q1 Loss Per Share Of $0.08

* AVENUE THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

BRIEF-Avenue Therapeutics Announces New Drug Application For IV Tramadol Accepted For Review By FDA

* AVENUE THERAPEUTICS ANNOUNCES NEW DRUG APPLICATION FOR IV TRAMADOL ACCEPTED FOR REVIEW BY FDA

Special Report: Biotech incubator taps investors through in-house brokerage

By Elizabeth Dilts, Benjamin Lesser, Carl O'Donnell and Michael Erman

BRIEF-Avenue Therapeutics Reports Q4 Loss Per Share $0.63

* AVENUE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

BRIEF-Avenue Therapeutics reports Q3 loss per share $0.30

* Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up